FDA Draft Guidance Provides Definitions, Recommendations For Custom Devices
This article was originally published in The Gray Sheet
FDA’s draft guidance defines terms used in its custom device exemption, which limits the production of such devices to “five units per year of a particular device type,” and provides recommendations for information to be included in annual reports.
You may also be interested in...
Congress has settled on final language for the FDA Safety and Innovation Act. After Senate approval, the bill will go to the White House for President Obama’s signature.
Acoramidis, AstraZeneca/BridgeBio Pharma's investigational treatment for patients with transthyretin amyloid cardiomyopathy, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Samsung Bioepis has received an EMA nod for its Sandoz-partnered Stelara biosimilar under the name Pyzchiva. Meanwhile, the agency’s CHMP also recommended granting centralized marketing authorizations for two Accord generics.